new treatment options against gram-negative organisms针对革兰氏阴性细菌的新治疗方案.pdfVIP

Bassetti et al. Critical Care 2011, 15:215 /content/15/2/215 R E V I E W New treatment options against gram-negative organisms Matteo Bassetti*, Francesca Ginocchio, Malgorzata Mikulska This article is one of eleven reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2011 (Springer Verlag) and co-published as a series in Critical Care. Other articles in the series can be found online at /series/annual. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from /series/8901 Introduction for Gram-negative pathogens. In fact, in 2004 the In recent years, infections caused by multi-drug resistant Infectious Diseases Society of America (IDSA) issued (MDR) pathogens have become a serious problem, their report, “Bad Bugs, No Drugs: As Antibiotic Dis- especially in the nosocomial setting. h e World Health covery Stagnates, A Public Health Crisis Brews,” which Organization (WHO) has identifi ed antimicrobial resis- proposed incentives to reinvigorate pharmaceutical tance as one of the three most important problems for investment in antibiotic research and development [2]. In human health. Some authors have summarized this 2007, the IDSA and the FDA repeated their call for an pheno menon with the word ‘ESKAPE’, to include the increase in new antibacterial research to develop next- most frequent MDR microorganisms: Enterococcus generation drugs [3]. Recently, the IDSA supported an faecium, Staphylococcus aureus, Klebsiella